寡转移性前列腺癌立体定向体部放疗长期无病生存的预测因素
该回顾性研究纳入234例≤3个激素敏感异时性寡转移前列腺癌患者,接受SBRT后中位随访56.5个月,5年rPFS、ADT-free生存和PCSS分别为22.9%、42.3%和96.4%。PSA倍增时间≤3个月与更短rPFS相关,同期ADT改善rPFS和ADT-free生存。
要点
- PSA倍增时间≤3个月是rPFS缩短的显著预测因素。
- 同期ADT使用与rPFS和ADT-free生存改善相关。
- 基线PSMA PET/CT诊断者中位ADT-free生存长于其他影像方法。
核心结论
- SBRT治疗激素敏感异时性寡转移前列腺癌5年后22.9%保持影像学无复发、42.3%保持无ADT生存。
研究设计与样本
- 2011至2023年英国Royal Marsden Hospital回顾性纳入234例≤3个激素敏感异时性寡转移前列腺癌患者,共治疗308个病灶。
主要发现
- 中位随访56.5个月,中位rPFS为22个月,中位ADT-free生存为42个月。
- 5年rPFS、ADT-free生存和PCSS分别为22.9%、42.3%和96.4%。
- PSA倍增时间≤3个月与更短rPFS显著相关[HR 1.52 (95%CI 1.07-2.16), P=.001]。
- 同期ADT使用改善rPFS[HR 0.52 (95%CI 0.37-0.73), P<.001]和ADT-free生存[HR 0.40 (95%CI 0.27-0.58), P<.001]。
- 基线PSMA PET/CT诊断者中位ADT-free生存52个月,其他影像方法为32个月(P=.041)。
关键数值与推荐
- 原发灶淋巴结病变与ADT-free生存负相关[HR 2.08 (95%CI 1.10-3.92), P=.023]。
- 寡转移灶>1个与ADT-free生存负相关[HR 1.88 (95%CI 1.25-2.82), P=.002]。
- 寡转移灶>1个与更差PCSS相关[HR 6.08 (95%CI 1.20-30.78), P=.029]。
- 原发灶淋巴结病变与更差PCSS相关[HR 6.48 (95%CI 1.16-36.15), P=.033]。
临床怎么用
- 对激素敏感异时性寡转移前列腺癌患者,SBRT前应评估PSA倍增时间、转移灶数目、原发灶淋巴结状态及诊断影像方法。
- 同期ADT使用与rPFS和ADT-free生存改善相关,但同期ADT未改善eugonadal rPFS和eugonadal ADT-free生存。
局限性
- 回顾性研究设计。
- 同期ADT由临床医生酌情决定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic body radiation therapy (SBRT) is increasingly used for oligometastatic prostate cancer, although most published series include mixed histologies and only a few patients achieve long-term disease-free survival. This retrospective study presents one of the largest prostate-only cohorts, aiming to identify who benefits most from SBRT. METHODS AND MATERIALS: From 2011 to 2023, 234 patients with ≤3 hormone-sensitive metachronous prostate cancer oligometastases were treated with SBRT at the Royal Marsden Hospital, London, and Sutton, UK. Concurrent androgen deprivation therapy (ADT) was allowed by clinician discretion. Treatment and outcome data were collected to assess the association between covariates and radiological progression-free survival (rPFS), ADT-free survival, and prostate cancer-specific survival (PCSS). RESULTS: In total, 308 lesions were treated in 234 patients. After a median follow-up of 56.5 months, median rPFS was 22 months and ADT-free survival was 42 months. The 5-year rPFS, ADT-free survival, and PCSS were 22.9%, 42.3%, and 96.4%, respectively. Concurrent ADT was used in 140 patients (59.8%). Prostate-specific antigen doubling time ≤ 3 months was a significant predictor for shorter rPFS [hazard ratio (95% CI) 1.52 (1.07-2.16), P = .001], and concurrent ADT use improved rPFS [0.52 (0.37-0.73), P < .001]. Nodal disease at primary presentation [2.08 (1.10-3.92), P = .023] and greater than 1 oligometastases [1.88 (1.25-2.82), P = .002] were inversely associated with ADT-free survival. Concurrent ADT use [0.40 (0.27-0.58), P < .001] improved ADT-free survival. Concurrent ADT use with SBRT did not improve eugonadal rPFS and eugonadal ADT-free survival. Patients diagnosed with oligometastases using baseline prostate-specific membrane antigen positron emission tomography/computed tomography had longer median ADT-free survival than those diagnosed with "other" imaging methods (52 vs 32 months, P = .041). For PCSS, more than 1 oligometastasis [6.08 (1.20-30.78), P = .029] and nodal disease at primary presentation [6.48 (1.16-36.15), P = .033] were associated with worse survival [5.95 (1.02-34.9), P = .048]. CONCLUSIONS: We present one of the largest SBRT case series specific to hormone-sensitive metachronous oligometastatic prostate cancer. After 5 years, 22.9% remained radiologically recurrence free and 42.3% remained ADT-free.
引用
- Yasar B, Chapman E, Taylor H, et al. Predictors of Long-Term Disease-Free Survival With Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer. Int J Radiat Oncol Biol Phys. 2025. PMID: 41325871. doi:10.1016/j.ijrobp.2025.11.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。